pharmaphorum

MARCH 12, 2021

Several cases of immune thrombocytopenia – a disorder characterised by low levels of blood platelets that can lead to bruising and bleeding – were reported in the European Medicines Agency’s safety surveillance database.

Vaccines 145

Vaccines Labelling Immunity Immunization 145

ALiEM - Pharm Pearls

OCTOBER 11, 2024

Immune thrombocytopenia (ITP) is an acquired autoimmune disorder caused by autoantibodies against platelet antigens. Common inciting events include viral infections, autoimmune diseases, or immunodeficiency syndromes [1]. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Physical Exam Vitals : 98.3°F;

Immunization 152

Immunization Immunity 152

pharmaphorum

DECEMBER 4, 2020

The 4 th Antigen Specific Immune Tolerance Digital Summit (ASIT) brings together industry representatives from the fields of autoimmunity, allergy, immuno-oncology and transplantation to tackle the complexities behind autoimmune disorders head on. The post 4th Antigen Specific Immune Tolerance Summit appeared first on.

Immunization 52

Immunization Immunity Medical Schools Drug Development 52

pharmaphorum

SEPTEMBER 1, 2020

Sanofi has drawn another blank in its attempt to repurpose its IL-6 drug Kevzara to tackle the extreme immune reaction seen in serious cases of COVID-19. In severe cases of COVID-19, patients suffer a “cytokine storm” where the immune system becomes overstimulated and attacks the body.

Immunity 111

Immunity Immunization Hospitals 111

Express Pharma

NOVEMBER 21, 2024

This innovation is designed to treat Community-Acquired Bacterial Pneumonia (CABP), a severe illness caused by drug-resistant bacteria, which disproportionately affects vulnerable populations, including children and the elderly as well as immune-compromised hosts like patients with diabetes, cancers etc.

Diabetes 105

Diabetes Immunization Immunity 105

pharmaphorum

JULY 6, 2021

While these types of tests are important, they don’t tell the whole story, as they can’t provide information on whether an individual has built an immune response to COVID-19, either through vaccination or through a previous infection. This is where antibody tests come in. ” . . The Importance of Antibody Certificates.

Immunization 111

Immunization Immunity Vaccines 111

European Pharmaceutical Review

DECEMBER 14, 2022

Personalised cancer vaccines are designed to prime the immune system so a patient can generate a tailored anti-tumour response specific to their tumour mutation signature. mRNA-4157/V940 stimulates an immune response by generating specific T cell responses based on the unique mutational signature of a patient’s tumour.

Vaccines 116

Vaccines Immunity Immunization 116

pharmaphorum

JANUARY 15, 2021

Latest data give hope that the vaccine could be added to the campaign after phase 1/2a data showed that the shot provided an immune response that lasted for at least 71 days, the duration of time measured in the study involving patients aged 18-55 years. J&J expects to file with the FDA first, followed by other regulators.

Vaccines 119

Vaccines Immunization Immunity 119

European Pharmaceutical Review

DECEMBER 15, 2023

Adverse events observed with mRNA-4157 in KEYNOTE-942 remain consistent with those previously reported. The most common adverse events were fatigue, injection site pain and chills. Keytruda is an immunotherapy that works by increasing the ability of the body’s immune system to help detect and fight tumour cells.

Vaccines 115

Vaccines Research Laboratories Immunity Immunization 115

European Pharmaceutical Review

SEPTEMBER 4, 2023

Included in Issue 4 of European Pharmaceutical Review : FOREWORD Dissolution testing – a dual role David Elder, David P Elder Consultancy REGULATORY INSIGHT EU packaging reform: a prescription for change?

Packaging 97

Packaging Vaccines Immunization Immunity 97

pharmaphorum

SEPTEMBER 30, 2020

As expected, patients in the study formed two populations: those who had already mounted an immune response and those whose immune response was not yet adequate. Serious adverse events occurred in 2 placebo patients, 1 low dose patient and no high dose patients. There were no deaths in the trial.

Immunity 135

Immunity Immunization 135

Express Pharma

FEBRUARY 1, 2024

Safety data from the trial have been reassuring with no serious adverse events linked to immunisation. It added, “R21/Matrix-M vaccine was well tolerated, with injection site pain and fever as the most frequent adverse events. Efficacy over this period was broadly similar across sites and in different transmission settings.

Vaccines 105

Vaccines Immunization Immunity 105

pharmaphorum

AUGUST 27, 2020

Moderna has said that its coronavirus vaccine stimulated an immune response in older people in phase 1 trials, suggesting that the jab is effective in the age groups most susceptible to COVID-19. There were also no serious adverse events reported. The company’s shares rose about 6% on the news.

Vaccines 111

Vaccines Immunization Immunity 111

European Pharmaceutical Review

AUGUST 2, 2023

This is an additional ingredient designed to trigger a stronger immune response. The vaccine demonstrated a strong immune response in the trial. In a clinical trial, this vaccine was shown to faciliate a strong immune response against the Omicron BA.1 1 variant, in addition to the original 2020 strain.

Vaccines 98

Vaccines Immunity Immunization 98

European Pharmaceutical Review

MARCH 26, 2024

Moderna’s next-generation COVID-19 vaccine mRNA-1283 demonstrated a higher immune response against SARS-CoV-2, interim results from the company’s Phase III trial show. These findings were based on data comparing the treatment to mRNA-1273.222 (Spikevax ® ), Moderna’s licensed vaccine for the condition.

Vaccines 110

Vaccines Immunization Immunity 110

European Pharmaceutical Review

NOVEMBER 24, 2022

Immune-mediated adverse reactions (ARs) occurred in 21 percent of patients treated with Libtayo ® and led to permanent discontinuation in 4.6 The most common immune-mediated ARs were hypothyroidism (6.8 percent), hyperthyroidism (3 percent), immune-mediated pneumonitis (2.6 percent), immune-mediated hepatitis (2.4

Chemotherapy 98

Chemotherapy Immunization Immunity Adverse Reactions 98

Express Pharma

AUGUST 22, 2024

Rybrevant is an EGFR- and MET-directed bispecific antibody that engages the immune system, and Lazcluze is a highly selective, brain-penetrant, third-generation oral EGFR TKI. Venous thromboembolic events (VTE) were observed with the combination. months versus 16.7 months), a secondary endpoint of the study.

Chemotherapy 96

Chemotherapy Immunization Immunity 96

Pharmaceutical Technology

MARCH 31, 2023

Moreover, these events also have ramifications for planned clinical trials. Eligibility for the UK’s National Health Services (NHS) booster programmes in England is restricted to those ages 75 years and above or individuals with weakened immune systems. The NHS will be using Covid-19 vaccines manufactured by Pfizer, Moderna and Sanofi.

Vaccines 110

Vaccines Immunization Immunity 110

pharmaphorum

FEBRUARY 10, 2021

Given the large unmet clinical need in this oncology indication and aligned with recent clinical trial progress, the Triple Negative Breast Cancer (TNBC) Drug Development Digital Summi t has been created to provide insight into industry- and academic-led clinical programs developing immune checkpoint, DDR inhibitor, ADC and other novel agents.

Drug Development 133

Drug Development Immunity Immunization Vaccines 133

PharmaShots

APRIL 5, 2023

Shots: The P-IIb dose-finding study evaluates vidofludimus calcium vs PBO in patients at 78 study sites in the US and EU The 50wk. maintenance phase results showed a dose-linear increase in clinical remission, 10 & 30mg, qd of vidofludimus calcium showed clinical remission rate (42.3% & 61.5%

Immunization 40

Immunization Immunity 40

Safe Biologics

FEBRUARY 4, 2025

Steqeyma is a human IL-12 and -23 antagonist indicated for multiple immune-mediated diseases, including psoriasis (PsO), psoriatic arthritis (PsA), Crohn’s disease (CD), ulcerative colitis (UC) in adults, and PsO and PsA in pediatric patients 6 years of age and older. Missed last month’s ASBM Newsletter? Read it here.

Biosimilars 130

Biosimilars Immunization Immunity 130

pharmaphorum

JANUARY 10, 2023

Other IgG proteases are being developed to tackle the issue of pre-existing immunity against AAV, but according to Selecta chief executive Carsten Brun these tend to be derived from common human pathogens – which means they themselves can be the target of existing antibodies. .”

Immunity 119

Immunity Immunization Drug Development 119

Pharmaceutical Technology

NOVEMBER 14, 2022

In lupus, the body’s immune system starts to attack its own cells. Saphnelo is also being studied in a Phase III trial in lupus nephritis, where a person’s immune system targets the kidneys, eventually leading to kidney failure. As per AstraZeneca's recent Q3 earnings, Saphnelo has yielded $69 million to date this year.

Immunity 144

Immunity Immunization 144

Pharmacy Joe

FEBRUARY 13, 2022

In this episode, I’ll discuss when rabies immune globulin is indicated. Episode 687: How to decide when to give rabies immune globulin? Subscribe on iTunes , Android , or Stitcher Rabies immune globulin (RIG) administration is part of successful rabies post-exposure prophylaxis. appeared first on Pharmacy Joe.

Immunization 40

Immunization Immunity Vaccines Inpatient 40

Pharmacy Joe

DECEMBER 18, 2024

The most common causes of acute liver failure were: viral hepatitis, drug-induced (but not from acetaminophen), auto-immune hepatitis and cause indeterminate. Only 1 of the 5 studies suggested an increase in adverse events with treatment, and this was only nausea and vomiting related events.

Hospitals 97

Hospitals Inpatient Immunization Immunity 97

pharmaphorum

NOVEMBER 27, 2024

The 10th Innate Killer Summit is a premier event organised by Hanson Wade, bringing together experts and thought leaders in the field of innate immunity and natural killer cells. Learn more about this event and how it can benefit you.

Immunization 52

Immunization Immunity 52

European Pharmaceutical Review

JULY 13, 2023

The field of immunotherapy is constantly evolving with the ultimate goal to develop new treatments that help the body’s immune system fight cancer. Immune cells, such as T cells and natural killer (NK) cells, have the inherent ability to combat diseases, including cancer, but are often inhibited by the body’s own suppressive mechanisms.

Immunization 98

Immunization Immunity Hospitals 98

European Pharmaceutical Review

SEPTEMBER 13, 2022

The current standard of care for patients with recurrent, unresectable or metastatic disease is immune checkpoint inhibitor monotherapy targeting anti-programmed death receptor 1 (anti-PD-1) and programmed death ligand 1 (PD-L1), but only about half of patients respond to this therapy.

Immunity 96

Immunity Immunization 96

European Pharmaceutical Review

JUNE 27, 2023

Participants with greater than 90 days of follow-up had elimination of severe hypoglycaemic events in the evaluation period. It is delivered by an infusion into the hepatic portal vein and requires chronic immunosuppressive therapy to protect the islet cells from immune rejection. This eliminates the need for immunosuppression.

Diabetes 98

Diabetes Immunization Immunity 98

Digital Pharmacist

JANUARY 16, 2023

From cancer prevention to diabetes awareness, these events help bring communities together. World Immunization Week: April 24-30. National Immunization Awareness Month. Also, don’t forget to promote these awareness events on your website and at your pharmacy. National Cancer Prevention Month. National Kidney Month.

Immunization 98

Immunization Immunity Vaccines Diabetes 98

pharmaphorum

MARCH 31, 2021

The decision to restrict use of the shot in under-60s comes from Germany’s independent vaccine committee known as STIKO made the decision based on available data about the blood clotting events. All but two of the 31 cases involved women aged 20 to 63 while two men affected were 36 and 57 years old, the institute said.

Vaccines 116

Vaccines Immunization Immunity 116

pharmaphorum

FEBRUARY 3, 2021

The emergence of novel base editing technologies that do not generate double-strand breaks (DSBs) offer a promising and safer alternative to fine-tune the next generation of immune cell therapies, especially as our need to perform complex multi-gene alterations increases. Another area for potential improvement is the source of immune cells.

Immunity 98

Immunity Immunization Vaccines 98

pharmaphorum

APRIL 12, 2021

Preclinical and early clinical data for modulators of the STING & TLR plus other innate immune checkpoint inhibitors has been hugely promising. View the event guide now for the full agenda details and speaker faculty. View the full event guide now. The post STING & TLR Targeting Therapies Summit appeared first on.

Immunity 52

Immunity Immunization Drug Development 52

European Pharmaceutical Review

OCTOBER 21, 2022

The incidence of serious adverse events was consistent with the age of the study population. No deaths or other Safety Adverse Events (SAE) considered related to vaccination were observed. Findings from the clinical trials illustrate it could override a person’s natural decline in immune response as they age.

Vaccines 105

Vaccines Immunization Immunity 105

pharmaphorum

FEBRUARY 18, 2021

The aim of the study is to find the smallest amount of SARS-CoV-2 that is needed to cause an infection, see how the immune system reacts to the virus, and to assist in the development of new treatments and vaccines. The study was first announced last year in a media briefing at the Wellcome Trust in London.

Vaccines 118

Vaccines Immunity Immunization 118

pharmaphorum

SEPTEMBER 11, 2022

With the results in hand, the developers of the therapy – from the Netherlands Cancer Institute and Norway’s National Center for Cancer Immune Therapy – say they now intend to file for regulatory approvals in Europe before the end of the year, without a commercial partner “to try to ensure that it remains affordable.”

Immunity 105

Immunity Immunization Chemotherapy Hospitals 105

Pharmacy Times

SEPTEMBER 14, 2023

Compared with COVID-19 vaccination alone, recent study findings show health care workers who received both a COVID-19 booster and influenza vaccinations did not have lower immune response or more frequent adverse events.

Vaccines 55

Vaccines Immunization Immunity 55